Operable breast cancer

Current Treatment Options in Oncology

Volumn 2, Issue 2, 2001, Pages 157-167

  Cianfrocca, Mary ^a   Goldstein, Lori J ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

Breast Cancer; Clin Oncol; Operable Breast Cancer; Paclitaxel; Tamoxifen

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CMF PROTOCOL; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; TAMOXIFEN;

ADJUVANT THERAPY; BREAST TUMOR; DISEASE FREE SURVIVAL; FEMALE; HUMAN; MORTALITY; MULTIMODALITY CANCER THERAPY; NEOPLASM; PRACTICE GUIDELINE; REVIEW; SURVIVAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CISPLATIN; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; FLUOROURACIL; HUMANS; METHOTREXATE; NEOADJUVANT THERAPY; NEOPLASMS, HORMONE-DEPENDENT; PRACTICE GUIDELINES; SURVIVAL ANALYSIS; TAMOXIFEN;

EID: 0035323137     PISSN: 15272729     EISSN: 15346277     Source Type: Journal    
DOI: 10.1007/s11864-001-0058-9     Document Type: Article

References (56)

1. Landis SH, Murray T, Bolden S, et al.: Cancer statistics, 1998. CA Cancer J Clin 1998, 48:6–29. DOI: 10.3322/canjclin.48.1.6
2. Mettlin C: Global breast cancer statistics. CA Cancer J Clin 1999, 49:138–144.
3. Bland KI, Menck HR, Scott-Connor CE, et al.:The National Cancer Data Base 10-year survey of breast cancer treatment at hospitals in the United States. Cancer 1998, 83:1262–1273. DOI: 10.1002/(SICI)1097-0142(19980915)83:6<1262::AID-CNCR28>3.0.CO;2-2
4. NIH Consensus Conference Recommendations available at www.nih.gov/news/pr/nov2000/omar-03.htm
5. Fisher B, Gebhardt MC: The evolution of breast cancer surgery: past, present and future. Semin Oncol 1978, 5:385.
6. Saez RA, McGuire WL, Clark GM: Prognostic factors in breast cancer. Semin Surg Oncol 1989, 5:102. DOI: 10.1002/ssu.2980050206
7. Nemoto T, Natarajan N, Bedwani R, et al.: Breast cancer in the medial half; results of the 1978 national survey of the American College of Surgeons. Cancer 1983, 51:1333. DOI: 10.1002/1097-0142(19830415)51:8<1333::AID-CNCR2820510802>3.0.CO;2-T
8. Fisher B, Bauer M, Wickerham DL, et al.: Relation of the number of positive axillary nodes to the prognosis of patients with primary breast cancer: an NSABP update. Cancer 1983, 52:1551. DOI: 10.1002/1097-0142(19831101)52:9<1551::AID-CNCR2820520902>3.0.CO;2-3
9. Fisher B, Slack NH, Bross IDJ, et al.: Cancer of the breast: size of neoplasm and prognosis. Cancer 1969, 24:1071. DOI: 10.1002/1097-0142(196911)24:5<1071::AID-CNCR2820240533>3.0.CO;2-H
10. Koscielny S, Tubiana M, Le MG, et al.: Breast cancer: relationship between the size of the primary tumour and the probability of metastatic dissemination. Br J Cancer 1984, 49:709.
11. Carter CL, Allen C, Henson DE: Relation of tumor size, lymph node status and survival in 24,740 breast cancer cases. Cancer 1989, 63:181. DOI: 10.1002/1097-0142(19890101)63:1<181::AID-CNCR2820630129>3.0.CO;2-H
12. Rosen PP, Groshen S, Saigo PE, et al.: Pathological prognostic factors in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma: a study of 644 patients with median follow-up of 18 years. J Clin Oncol 1989, 7:1239.
13. Andrulis IL, Bull SB, Blackstein ME, et al.: neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. J Clin Oncol 1998, 16:1340–1349.
14. Slamon DJ, Clark GM, Wong SG, et al.: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177–182. DOI: 10.1126/science.3798106
15. Allred DC, Clark GM, Tandon AK, et al.: HER-2/ neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol 1992, 10:599–605.
16. Paik S, Bryant J, Park C, et al.: erbB-2 and response to doxorubicin in patients with axillary lymph nodepositive hormone receptor-negative breast cancer. J Natl Cancer Inst 1998, 90:1361–1370. DOI: 10.1093/jnci/90.18.1361
17. Thor AD, Berry DA, Budman DR, et al.: erbB-2, p53, and efficacy of adjuvant therapy in lymph nodepositive breast cancer. J Natl Cancer Inst 1998, 90:1346–1360. DOI: 10.1093/jnci/90.18.1346
18. Hutchins l, Green S, Ravdin P, et al.: CMF versus CAF with and without tamoxifen in high-risk nodenegative breast cancer patients and a natural history follow-up study in low-risk node-negative patients: first results of intergroup trial INT 0102. Proc ASCO 1998, 17:2.
19. Swain SM, Sorace RA, Bagley CS, et al.: Neoadjuvant chemotherapy in the combined modality approach of locally advanced nonmetastatic breast cancer. Cancer Res 1987, 47:3889.
20. Balawajder I, Antich PP, Boland J: An analysis of the role of radiotherapy alone and in combination with chemotherapy and surgery in the management of advanced breast cancer. Cancer 1983, 51:574. DOI: 10.1002/1097-0142(19830215)51:4<574::AID-CNCR2820510403>3.0.CO;2-B
21. Hortobagyi GN, Blumenschein GR, Spanos W, et al.:Multimodality treatment of locoregionally advanced breast cancer. Cancer 1983, 51:763. DOI: 10.1002/1097-0142(19830301)51:5<763::AID-CNCR2820510502>3.0.CO;2-C
22. Perloff M, Lesnick GJ, Korzun A, et al.: Combination chemotherapy with mastectomy or radiotherapy for stage III breast carcinoma: a cancer and leukemia group B study. J Clin Oncol 1998, 6:261.
23. Bonadonna G, Valagussa P, Brambilla C, et al.: Adjuvant and neoadjuvant treatment of breast cancer with chemotherapy and/or endocrine therapy. Semin Oncol 1991, 18:515–524.
24. Fisher B, Brown A, Mamounas E, et al.: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997, 15:2483.
25. Fisher B, Bryant J, Wolmark N, et al.: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998, 16:2672.
26. Cole MP: A clinical trial of artificial menopause in carcinoma of the breast. INSERM 1975, 55:143.
27. Early Breast Cancer Trialists’ Collaborative Group: Ovarian ablation in early breast cancer: overview of the randomised trials. Lancet 1996, 348:1189–1196. DOI: 10.1016/S0140-6736(05)66228-9
28. Early Breast Cancer Trialists’ Collaborative Group: Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998, 351:1451–1467. Details the benefits of tamoxifen as adjuvant therapy for primary breast cancer. DOI: 10.1016/S0140-6736(97)11423-4
29. Fisher B, Digham J, Bryant J, et al.: Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 1996, 88:1529–1542. DOI: 10.1093/jnci/88.21.1529
30. Tormey DC, Gray R, Falkson HC: Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. J Natl Cancer Inst 1996, 88:1828. DOI: 10.1093/jnci/88.24.1828
31. Stewart HJ, Forrest AP, Everington D, et al.: Randomized comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. The Scottish Cancer Trials Breast Group. Br J Cancer 1996, 74:297.
32. Fisher B, Constantino JP, Wickerham Dl, et al.: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998, 90:1371–1388. DOI: 10.1093/jnci/90.18.1371
33. Early Breast Cancer Trialists’ Collaborative Group: Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 1998, 352:930–942. Details the benefits of polychemotherapy as adjuvant therapy for primary breast cancer. DOI: 10.1016/S0140-6736(05)61359-1
34. Fisher B, Anderson S, Wolmark N, et al.: Chemotherapy with or without tamoxifen for patients with ER negative cancer and negative nodes: results from NSABP B23. Proc Am Soc Clin Oncol 2000, 19:277.
35. Levine MN, Bramwell VH, Pritchard KI, et al.: Randomized trial of intensive cyclophosphamide, epirubicin and 5-fluorouracil chemotherapy compared with cyclophosphamide, methotrexate and 5-fluorouracil in premenopausal women with node-positive breast cancer. J Clin Oncol 1998, 16:2651–2658.
36. Bonneterre J, Roche H, Bremond A, et al.: Results of a randomized trial of adjuvant chemotherapy with FEC-50 versus FEC-100 in high-risk node-positive breast cancer patients. Proc ASCO 1998, 17:473.
37. Henderson IC, Berry D, Demetri G, et al.: Improved disease-free (DFS) and overall survival (OS) from the addition of sequential paclitaxel (T) but not from the escalation of doxorubicin (A) dose level in the adjuvant chemotherapy of patients (PTS) with node-positive primary breast cancer (BC). Proc ASCO 1998, 17:101a.
38. Fisher B, Anderson S, Wickerham DL, et al.: Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22. J Clin Oncol 1997, 15:1858.
39. Fisher B, Anderson S, DeCillis A, et al.: Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-25. J Clin Oncol 1999, 17:3374–3388.
40. Peters W, Rosner G, Vredenburgh J, et al.: A prospective, randomized comparison of two doses of combination alkylating agents (AA) as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes (LN): preliminary results of CALGB 9082/SWOG 9114/NCIC ma-13. Proc Am Soc Clin Oncol 1999, 18:2.
41. The Scandinavian Breast Cancer Study Group 9401: Results from a randomized adjuvant breast cancer study with high dose chemotherapy with CTCb supported by autologous bone marrow stem cells versus dose escalated and tailored FEC therapy. Proc Am Soc Clin Oncol 1999, 18:3.
42. Weiss RB, Rifkin RM, Stewart FM, et al.: High-dose chemotherapy for high-risk primary breast cancer: an on-site review of the Bezwoda study. Lancet 2000, 355:999–1003. DOI: 10.1016/S0140-6736(00)90024-2
43. Bryce CJ, Shenker T, Gelmon K, et al.: Menstrual disruption in premenopausal breast cancer patients receiving CMF (IV) vs AC adjuvant chemotherapy. Br Cancer Tx Res 1998, 50:336.
44. The International Breast Breast Cancer Group: Late effects of adjuvant oophorectomy and chemotherapy upon premenopausal breast cancer patients. Ann Oncol 1990, 1:30.
45. Rivkin S, Green S, Metch B, et al.: Adjuvant combination chemotherapy (CMFP) vs. oophorectomy followed by CMFP (OCMFP) for premenopausal women with ER+ operable breast cancer with positive axillary lymph nodes: an intergroup study. Proc Am Soc Clin Oncol 1991, 10:47.
46. Davidson N, O’Neill A, Vukov A, et al.: Effect of chemohormonal therapy in premenopausal, node +, receptor + breast cancer: an Eastern Cooperative Oncology Group Phase III Intergroup Trial (E5188, INT-0101). Proc Am Soc Clin Oncol 1999, 18:249.
47. Fisher B, Dignam J, Wolmark N, et al.: Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst 1997, 89:1673–1682. DOI: 10.1093/jnci/89.22.1673
48. Hutchins I, Green S, Ravdin P, et al.: CMF versus CAF with and without tamoxifen in high-risk nodenegative breast cancer patients and a natural history follow-up study in low-risk node-negative patients: update of tamoxifen results. Br Cancer Res Tx 1999, 57:1. DOI: 10.1023/A:1017233217253
49. Fisher B, Redmond C, Legault-Poisson S, et al.: Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of nodepositive breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16. J Clin Oncol 1990, 8:1005.
50. Albain K, Green S, Osborne K, et al.: Tamoxifen vs. cyclophosphamide, adriamycin, and 5-FU plus either concurrent or sequential tamoxifen in post-menopausal receptor+ node+ breast cancer: a Southwestern Oncology Group Phase III Intergroup Trial (SWOG-8814, Int-0100). Proc Am Soc Clin Oncol 1997, 16:450.
51. Holmes FA, Newman RA, Madden V, et al.: Schedule dependent pharmacokinetics (PK) in a phase I trial of taxol (T) and doxorubicin (D) as initial chemotherapy for metastatic breast cancer (abstract). In Proceedings of the 8th NCI-EORTC Symposium on New Drugs in Cancer Therapy, Amsterdam, March 15–18, 1994: Dordrecht, Netherlands, Kluwer; 1994:197.
52. Hillner BE, Smith TJ: Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer. N Engl J Med 1991, 324:160. DOI: 10.1056/NEJM199101173240305
53. Smith TJ, Hillner BE: The efficacy and cost effectiveness of adjuvant therapy of early breast cancer in premenopausal women. J Clin Oncol 1993, 11:771.
54. Desch CE, Hillner BE, Smith TJ, et al.: Should the elderly receive chemotherapy for node-negative breast cancer? A cost effectiveness analysis examining total and active life-expectancy outcomes. J Clin Oncol 1993, 11:777.
55. Siminoff LA, Fetting JH, Abeloff MD: Doctor-patient communication about breast cancer therapy. J Clin Oncol 1989, 7:1192.
56. Rajagopal S, Goodman PF, Tannock IF: Adjuvant chemotherapy for breast cancer: discordance between physicians’perceptions of benefit and the results of clinical trials. J Clin Oncol 1994, 12:1296.